Unibest

Pharmaceutical intermediates

Finerenone Intermediates

6 pharmaceutical intermediates for Finerenone. Indication: Chronic Renal Insufficiency.

提交项目All intermediates

About Finerenone

Originator
Bayer Healthcare Pharmaceuticals Inc
Indication
Chronic Renal Insufficiency
Approved Date
07/09/2021
NCE Patent
07/09/2026
DS/DP
04/12/2029

Available intermediates

6 intermediates currently listed for Finerenone. Request specifications, documentation or a quotation for any item below.

Finerenone intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Bromo-2-methoxybenzaldehyde43192-33-2//
4-formyl-3-methoxybenzonitrile21962-45-8//
4-AMino-5-Methylpyridin-2-ol95306-64-2//
2-chloro-5-methylpyridin-4-amine79055-62-2//
2-Cyanoethyl 3-oxobutanoate65193-87-5//
2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate1050477-43-4//

Other programs under F

FebuxostatFexuprazan HClFezolinetantFilgotinib MaleateFluralanerFostamatinib disodium hexahydrateFruquintinibFutibatinib

Building toward Finerenone?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →